“Goodbye, implants!” Claims like this travel quickly on social media, accompanied by striking digital animations. Behind the sensational framing lies genuine research into dental tissue regeneration and the possibility of forming new teeth. Yet repairing pulp or periodontal tissues is fundamentally different from growing a complete functional tooth.
As of November 2026, predictable whole-tooth regeneration is not an established or routinely available human treatment. The three approaches below are promising but remain at different stages of development.
USAG-1 (SOSTDC1) is involved in regulating pathways that contribute to tooth development. In 2021, an animal study showed that antibodies against USAG-1 could influence tooth formation by modulating BMP signalling [1]. These preclinical findings demonstrate biological potential, not established clinical efficacy in humans.
TRG035 is an investigational monoclonal antibody developed by Japan-based Toregem BioPharma, initially targeting certain forms of congenital tooth agenesis. Its Phase I trial was registered in 2024, with safety as the primary outcome and pharmacokinetic outcomes assessed secondarily [2]. On 17 August 2026, the company announced that Japan’s PMDA had completed the required investigation of the notification for a planned Phase IIa trial [3]. This was not marketing approval or proof that the drug regrows lost teeth in people.
Research includes dental pulp stem cells (DPSCs), stem cells from exfoliated deciduous teeth (SHED), stem cells from the apical papilla (SCAP), and periodontal ligament stem cells (PDLSCs). These populations are investigated for regeneration of pulp-like tissues, dentin, periodontal tissues and alveolar bone.
Early human clinical studies have shown encouraging but limited results. A five-patient pilot study published in 2017 investigated autologous dental pulp stem-cell transplantation [4]. A 2018 study investigated dental pulp regeneration using stem cells from deciduous teeth [5]. These studies do not establish routine regeneration of a complete tooth.
Emerging biofabrication approaches combine computer-aided design (CAD), computer-aided manufacturing (CAM), biomaterial scaffolds, bioinks, living cells and tissue engineering. Unlike conventional restorative CAD/CAM, which manufactures prostheses, biofabrication aims to organise living components into patient-specific structures [6, 7].
Biological CAD/CAM is best understood as an enabling technological platform rather than an independent biological mechanism. Most dental tissue bioprinting evidence remains preclinical, and barriers include vascularisation, innervation, mechanical integration, reproducibility and regulation [7].
A whole functional human tooth requires coordinated development of enamel, dentin, pulp, root structures, periodontal attachment, blood supply and innervation, along with functional integration into the jaw. This remains a major translational challenge [6].
No. As of 14 November 2026, complete biological tooth regeneration is not an established, predictable substitute for dental implants in patients with acquired tooth loss. Implants, bridges and removable prostheses remain important options according to clinical indications. Necessary dental care should not be delayed on the basis of viral claims.
Laser Dental Clinic follows developments in regenerative medicine, dental stem-cell research, molecular strategies and digital biofabrication. Through “Third Dentition — Between Science and Hope,” we will distinguish experimental findings from clinically established methods, with particular attention to patient safety, effectiveness and long-term function.
“Sustainable health is harmony, balance, and synchronicity.”
This article is for educational purposes and does not constitute individual medical advice.